Indenolol je beta-adrenergijski blokator[4] za lečenje hipertenzije (visokog krvnog pritiska). Istražen je tokom 1980-ih,[5] ali prema podacima iz 2021. godine nije poznato da li će biti plasiran na tržište.[6] On je derivat fenolnog 4-indenola.
^Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
^Ali, I; Gaitonde, VD; Aboul-Enein, HY; Hussain, A (2009). „Chiral separation of beta-adrenergic blockers on CelluCoat column by HPLC”. Talanta. 78 (2): 458—63. PMID19203609. doi:10.1016/j.talanta.2008.11.043.
^Trimarco, Bruno; Cuocolo, Alberto; Groothold, Gisela; Ricciardelli, Bruno; De Luca, Nicola; Volpe, Massimo; Veniero, Anna Maria; Condorelli, Mario (1985). „Indenolol: A New Antihypertensive Agent: Efficacy, Toxicity, and Hemodynamic Effects in a Crossover Double-Blind Study with Metoprolol”. The Journal of Clinical Pharmacology. 25 (5): 328—336. PMID4031109. S2CID22844379. doi:10.1002/j.1552-4604.1985.tb02850.x.